DFTX
Definium Therapeutics, Inc.Company Information
- Company Name
- Definium Therapeutics, Inc.
- CIK
- CIK0001813814
- Category
- <br>Emerging growth company
- Ticker: Exchange
- DFTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2833
- SIC Description
- Medicinal Chemicals & Botanical Products
- Ticker
- DFTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-12-05
- Last sale
- 2026-06-25
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 234,558
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 73,933,286
- Shares outstanding
- 108,790,941
- Ownership
- 67.96%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -11.18%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 655 | 263 | 258 | 20 | 33 | 83 | 274 | 295 | 243 | 252 | 100 | 118 | ||||||
| Short Term Investments | 429 | 111 | 154 | 189 | 150 | 130 | 0 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 8 | 7 | 8 | 7 | 6 | 9 | 8 | 4 | 5 | 3 | 4 | 2 | ||||||
| Assets Current | 1,092 | 381 | 419 | 216 | 189 | 222 | 282 | 299 | 248 | 255 | 104 | 120 | ||||||
| Goodwill | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Indefinite Lived Intangible Assets Excluding Goodwill | - | - | - | - | - | - | - | - | - | - | 1 | 1 | ||||||
| Long Term Investments | - | - | - | - | 55 | 33 | - | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | ||||||
| Assets | 1,113 | 401 | 440 | 237 | 265 | 275 | 302 | 320 | 268 | 276 | 125 | 142 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 7 | 7 | 5 | 8 | 4 | 2 | 2 | 2 | 3 | 8 | 4 | 8 | ||||||
| Accrued Liabilities Current | 37 | 25 | 20 | 19 | 15 | 11 | 13 | 9 | 8 | 10 | 12 | 10 | ||||||
| Liabilities Current | 157 | 81 | 67 | 65 | 38 | 30 | 39 | 33 | 42 | 65 | 32 | 31 | ||||||
| Long Term Line Of Credit | 36 | 41 | 41 | 40 | 41 | 22 | 22 | 24 | 24 | 14 | 14 | 14 | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 0 | 1 | 1 | - | - | - | - | 0 | 0 | 0 | ||||||
| Liabilities | 194 | 122 | 108 | 106 | 80 | 53 | 61 | 58 | 66 | 79 | 46 | 46 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | - | - | - | - | - | - | 0 | 0 | 0 | - | 0 | - | ||||||
| Additional Paid In Capital Common Stock | 1,737 | 938 | 914 | 662 | 650 | 644 | 640 | 626 | 552 | 540 | 368 | 362 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | ||||||
| Retained Earnings Accumulated Deficit | -819 | -660 | -583 | -532 | -465 | -422 | -399 | -364 | -350 | -345 | -290 | -266 | ||||||
| Stockholders Equity | 919 | 279 | 332 | 131 | 185 | 223 | 241 | 262 | 202 | 196 | 78 | 96 | ||||||
| Liabilities And Stockholders Equity | 1,113 | 401 | 440 | 237 | 265 | 275 | 302 | 320 | 268 | 276 | 125 | 142 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Issued | 134 | 104 | 99 | 77 | 76 | 76 | 75 | 82 | 72 | 71 | 41 | 40 | ||||||
| Shares Outstanding | 134 | 104 | 99 | 77 | 76 | 76 | 75 | 82 | 72 | 71 | 41 | 40 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialDefinium Therapeutics, Inc. (DFTX) — SEC Financial Statements & Analysis
Definium Therapeutics, Inc. (DFTX) is a medicinal chemicals & botanical products company, incorporated in A1. Definium Therapeutics, Inc. trades on Nasdaq as: DFTX. Definium Therapeutics, Inc. (DFTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Definium Therapeutics, Inc. carries a market cap of $5.21B, a P/E ratio of -14.72x, a P/B ratio of 5.67x, an enterprise value of $4.55B, and an EV/EBITDA multiple of -20.00x. On profitability, it posts a Return on Equity (ROE) of -64.09%, a Return on Assets (ROA) of -51.35%, and a Return on Invested Capital (ROIC) of -109.55%. Per share, it reports EPS of $-3.20, diluted EPS of $-3.20, free cash flow per share of $-1.52, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 208.94% year-over-year and EPS growth of 138.22% year-over-year. On the balance sheet, it maintains a current ratio of 6.95x, a quick ratio of 6.89x, working capital of $934.90M, a debt-to-equity ratio of 0.21x, a debt ratio of 0.17, an interest coverage ratio of -45.33x, free cash flow of $-167.95M (TTM), and net debt of $-655.27M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.21B
- P/E TTM
- -14.72x
- EPS TTM
- $-3.20
- P/B TTM
- 5.67x
- ROE TTM
- -64.09%
- ROA TTM
- -51.35%
- Debt To Equity
- 0.21x
- Free Cash Flow TTM
- $-167.95M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Definium Therapeutics, Inc. in?
Definium Therapeutics, Inc. (DFTX) operates in the Medicinal Chemicals & Botanical Products industry.
What exchange does DFTX trade on?
Definium Therapeutics, Inc. (DFTX) trades on the Nasdaq.
Where is Definium Therapeutics, Inc. incorporated?
Definium Therapeutics, Inc. is incorporated in British Columbia, Canada.
When was Definium Therapeutics, Inc. (DFTX)'s most recent SEC filing?
Definium Therapeutics, Inc. (DFTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is DFTX's market cap?
Definium Therapeutics, Inc. (DFTX) has a market capitalization of $5.21B as of 2026-06-30.
What is DFTX's EPS (earnings per share)?
Definium Therapeutics, Inc. (DFTX)'s trailing twelve month EPS is $-3.20 as of 2026-06-30.
What is DFTX's ROE (return on equity)?
Definium Therapeutics, Inc. (DFTX)'s trailing twelve month Return on Equity (ROE) is -64.09% as of 2026-06-30.
What is DFTX's ROA (return on assets)?
Definium Therapeutics, Inc. (DFTX)'s trailing twelve month Return on Assets (ROA) is -51.35% as of 2026-06-30.
What is DFTX's ROIC (return on invested capital)?
Definium Therapeutics, Inc. (DFTX)'s trailing twelve month Return on Invested Capital (ROIC) is -109.55% as of 2026-06-30.
What is DFTX's EV/EBITDA?
Definium Therapeutics, Inc. (DFTX)'s trailing twelve month EV/EBITDA is -20.00x as of 2026-06-30.